3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Conditions
Neoplasms
165
Breast Neoplasms
163
Carcinoma, Non-Small-Cell Lung
143
Colorectal Neoplasms
101
Prostatic Neoplasms
99
Lung Neoplasms
86
Ovarian Neoplasms
78
Neoplasm Metastasis
72
Multiple Myeloma
71
Pancreatic Neoplasms
67
Leukemia, Myeloid, Acute
59
Endometrial Neoplasms
47
Squamous Cell Carcinoma of Head and Neck
44
Lymphoma
42
Stomach Neoplasms
41
Recurrence
40
Melanoma
39
Glioblastoma
39
Carcinoma, Renal Cell
39
Brain Neoplasms
39
Carcinoma, Hepatocellular
38
Urinary Bladder Neoplasms
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
37
Lymphoma, Non-Hodgkin
34
Leukemia, Lymphocytic, Chronic, B-Cell
34
Hematologic Neoplasms
34
Glioma
34
Sarcoma
33
Esophageal Neoplasms
31
Small Cell Lung Carcinoma
30
Interventions
apixaban
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Pulmonary Embolism
×
30 days
×
Clear all
NCT07493304
2026-05-29
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3
Recruiting
1,600 enrolled
NCT07410117
2026-05-27
ROXI-CAT-I
Regeneron Pharmaceuticals
Phase 3
Recruiting
1,120 enrolled